A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
LOXO-BTK-18001 BRUIN
Phase 2 other active
Quick answer
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)" is a Phase 2 program (other) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ology Bioservices Ireland LTD
- Indication
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"
- Phase
- Phase 2
- Modality
- other
- Status
- active